98%
921
2 minutes
20
Background & Aims: In above-average-risk individuals undergoing colonoscopy-based surveillance for colorectal cancer (CRC), screening with fecal immunochemical tests (FIT) between colonoscopies might facilitate personalization of surveillance intervals. Because a negative FIT is associated with a reduced risk for CRC, we examined the relationship between number of rounds of negative FIT and risk for advanced neoplasia in individuals undergoing surveillance colonoscopy.
Methods: We conducted a retrospective cohort study on 4021 surveillance intervals in 3369 individuals (50-74 years), who had completed a 2-sample FIT between colonoscopies, from 1 to 4 rounds at 1-2 yearly intervals, each with a negative result (<20 μg hemoglobin/g feces). Incidence of advanced neoplasia (CRC or advanced adenoma) was determined at the follow-up colonoscopy. Competing-risk regression was used to assess the association between multiple negative FIT results and the risk of advanced neoplasia within 2 years.
Results: The incidence of advanced neoplasia in the cohort was 9.9% and decreased with increasing numbers of rounds of negative FIT results: 11.1% after 1 negative FIT to 5.7% after 4 negative FIT. The risk of advanced neoplasia was significantly lower in participants with 3 (subdistribution hazard ratio, 0.50; 95% confidence interval, 0.24-0.97) and 4 (subdistribution hazard ratio, 0.33; 95% confidence interval, 0.15-0.73) rounds of negative FIT compared with only 1 negative FIT.
Conclusions: There was a low risk of advanced neoplasia after multiple rounds of negative FIT in above-average-risk people undergoing surveillance with no neoplasia or nonadvanced adenoma at prior colonoscopy. This supports the use of interval FIT to personalize surveillance by lengthening colonoscopy intervals following multiple negative FIT results.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.cgh.2022.12.024 | DOI Listing |
Public Health
September 2025
Department of Public Health, Erasmus MC University Medical Center, Rotterdam, the Netherlands.
Objectives: Participation rates in fecal immunochemical test (FIT)-based colorectal cancer (CRC) screening differ across socio-demographic subgroups. The largest health gains could be achieved in subgroups with low participation rates and high risk of CRC. We investigated the CRC risk within different socio-demographic subgroups with low participation in the Dutch CRC screening program.
View Article and Find Full Text PDFClin Gastroenterol Hepatol
September 2025
Division of Gastroenterology and Hepatology, Department of Medicine, Indiana University School of Medicine; Center for Health Information and Communication, Health Services Research and Development, Richard L. Roudebush, VA Medical Center; The Regenstrief Institute, Inc; The Melvin and Bren Simon Co
JAMA Netw Open
September 2025
Public Health Sciences Division, Fred Hutchinson Cancer Center, Seattle, Washington.
Importance: In colorectal cancer (CRC) screening, too many patients fail to receive follow-up colonoscopy after an abnormal fecal immunochemical test (FIT), and transportation is a frequently reported barrier.
Objective: To determine the outcomes and cost-effectiveness of providing a rideshare intervention to patients with abnormal FIT results.
Design, Setting, And Participants: The CRC-Simulated Population Model for Incidence and Natural History microsimulation model was used to simulate the outcomes and cost-effectiveness of a rideshare intervention to improve colonoscopy completion in a population-based CRC screening program.
Pharmacoecon Open
September 2025
Centre for Health Systems and Policy Research, JC School of Public Health and Primary Care, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong, China.
Objectives: This study aims to quantify the preference of adults below 50 years of age for fecal immunochemical test (FIT) options as screening for colorectal cancer (CRC) and its disparities across different subgroups.
Methods: A discrete choice experiment (DCE) was conducted among adults aged < 50 years old in Hong Kong. A mixed logit model and latent class model were used to estimate their preference, taking into account their preference heterogeneity.
Can J Gastroenterol Hepatol
September 2025
Department of Gastroenterology, St Luke's General Hospital, Kilkenny, Ireland.
The faecal immunochemical test (FIT) is endorsed by NICE for triaging symptomatic patients referred from primary care. This prospective diagnostic accuracy study assessed the performance of FIT in detecting significant colorectal pathology among symptomatic patients referred for colonoscopy in secondary care. Between May 2023 and May 2024, FIT kits were distributed to 1296 adult patients referred for lower gastrointestinal (GI) endoscopy.
View Article and Find Full Text PDF